BlackRock Health Sciences Trust Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BlackRock Health Sciences Trust in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BlackRock Health Sciences Trust stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BME, but not buy additional shares or sell existing shares.
View analyst ratings for BlackRock Health Sciences Trust or view top-rated stocks.

Wall Street analysts have given BlackRock Health Sciences Trust a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BlackRock Health Sciences Trust wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

BlackRock Health Sciences Trust saw a decrease in short interest during the month of January. As of January 29th, there was short interest totaling 34,700 shares, a decrease of 21.5% from the January 14th total of 44,200 shares. Based on an average daily trading volume, of 34,900 shares, the days-to-cover ratio is currently 1.0 days.
View BlackRock Health Sciences Trust's Short Interest.

BlackRock Health Sciences Trust's stock was trading at $37.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BME shares have increased by 28.5% and is now trading at $47.88.
View which stocks have been most impacted by COVID-19.

BlackRock Health Sciences Trust declared a monthly dividend on Monday, February 1st. Stockholders of record on Tuesday, February 16th will be paid a dividend of $0.20 per share on Friday, February 26th. This represents a $2.40 annualized dividend and a yield of 5.01%. The ex-dividend date is Friday, February 12th.
View BlackRock Health Sciences Trust's dividend history.

BlackRock Health Sciences Trust pays an annual dividend of $2.40 per share and currently has a dividend yield of 0.06%.
View BlackRock Health Sciences Trust's dividend history.

3 employees have rated BlackRock Health Sciences Trust CEO Javier Hernani Burzako on Glassdoor.com. Javier Hernani Burzako has an approval rating of 100% among BlackRock Health Sciences Trust's employees. This puts Javier Hernani Burzako in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to BlackRock Health Sciences Trust include Adams Diversified Equity Fund (ADX), Calamos Global Dynamic Income Fund (CHW), Cohen & Steers Quality Income Realty Fund (RQI), Macquarie/First Trust Global Infrastructure/Utilities Dividend & Income Fund (MFD), Nuveen Tax-Advantaged Total Return Strategy Fund (JTA), Reaves Utility Income Fund (UTG) and The Gabelli Dividend & Income Trust (GDV).
View all of BME's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BlackRock Health Sciences Trust investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), AT&T (T), Gilead Sciences (GILD), International Business Machines (IBM), Johnson & Johnson (JNJ), Verizon Communications (VZ), Exxon Mobil (XOM), Alibaba Group (BABA) and The Procter & Gamble (PG).

BlackRock Health Sciences Trust trades on the New York Stock Exchange (NYSE) under the ticker symbol "BME."

BlackRock Health Sciences Trust's stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Stanley (0.00%), Wells Fargo & Company MN (0.00%), Ahrens Investment Partners LLC (0.00%), Cambridge Investment Research Advisors Inc. (0.00%), LPL Financial LLC (0.00%) and HighTower Advisors LLC (0.00%).
View institutional ownership trends for BlackRock Health Sciences Trust.

BME stock was sold by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc., Blue Bell Private Wealth Management LLC, HighTower Advisors LLC, Truist Financial Corp, and Janney Montgomery Scott LLC.
View insider buying and selling activity for BlackRock Health Sciences Trust or view top insider-selling stocks.

BME stock was acquired by a variety of institutional investors in the last quarter, including Ahrens Investment Partners LLC, Diversified LLC, Wells Fargo & Company MN, LPL Financial LLC, Kestra Advisory Services LLC, Morgan Stanley, M&T Bank Corp, and Cambridge Investment Research Advisors Inc..
View insider buying and selling activity for BlackRock Health Sciences Trust or or view top insider-buying stocks.

Shares of BME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BME stock can currently be purchased for approximately $47.88.

The official website for BlackRock Health Sciences Trust is www2.blackrock.com.

BlackRock Health Sciences Trust is headquartered at 100 Bellevue Pkwy, WILMINGTON, DE 19809-3700, United States.

BlackRock Health Sciences Trust's mailing address is 100 Bellevue Pkwy, WILMINGTON, DE 19809-3700, United States. The company can be reached via phone at +1-800-8820052.